Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised phase III trial of paclitaxel plus carboplatin (TC) therapy versus irinotecan plus cisplatin (CPT-P) therapy as a first line chemotherapy for clear cell carcinoma of the ovary.

Trial Profile

Randomised phase III trial of paclitaxel plus carboplatin (TC) therapy versus irinotecan plus cisplatin (CPT-P) therapy as a first line chemotherapy for clear cell carcinoma of the ovary.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2018

At a glance

  • Drugs Cisplatin (Primary) ; Irinotecan (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CCC-1; GCIG; JGOG 3017
  • Most Recent Events

    • 07 Jan 2014 Planned number of patients changed from 662 to 652 as reported in ISRCTN: Current Controlled Trials & European Clinical Trials Database records.
    • 27 Jun 2012 Additional lead trial centre identified as reported by EudraCT.
    • 27 Jul 2011 Actual end date (31 Dec 2010) added as reported by as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top